99.50USD+0.90%Mkt Cap: 6.04B USDP/E: —Last update: 2026-05-26
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap6.04B USD
Enterprise Value6.08B USD
Revenue (TTM)569.61M USD
Gross Profit421.07M USD
Net Income (TTM)-23.36M USD
Revenue/Share10.81 USD
Last Price99.50 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees418
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS6047491013
Valuation
P/E (Trailing)—
P/E (Forward)-180.41
PEG—
EV/EBITDA-121.41
EV/Revenue10.67
P/S10.78
P/B25.29
EPS (TTM)-13.60
EPS (Forward)-0.56
52W Range
42.8979% of range114.99
52W High114.99 USD
52W Low42.89 USD
Profitability
Gross Margin80.77%
Oper. Margin-39.51%
EBITDA Margin-8.79%
Profit Margin-4.48%
ROE-7.42%
ROA-2.77%
Growth
Revenue Growth43.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF55.83M USD
CapEx (TTM)954.00K USD
FCF Margin29.30%
FCF Yield2.76%
Net Debt-62.48M USD
Net Debt/EBITDA1.25
Balance Sheet
Debt/Equity1.02
Current Ratio2.09
Quick Ratio1.90
Book Value/Sh3.980 USD
Cash/Share6.334 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)144.15 USD
Target Range115.00 USD – 185.00 USD
# Analysts13
Ownership
Shares Out.60.98M
Float52.48M
Insiders1.35%
Institutions114.85%
Short Interest
Short Ratio11.5d
Short % Float18.10%
Short % Out.13.80%
Shares Short8.41M
Short (prev mo.)8.05M
Technical
SMA 5096.39 (+3.2%)
SMA 20083.31 (+19.4%)
Beta0.52
S&P 52W Chg28.31%
Avg Vol (30d)1.04M
Avg Vol (10d)1.60M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—